1. Home
  2. IDYA vs PHIN Comparison

IDYA vs PHIN Comparison

Compare IDYA & PHIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • PHIN
  • Stock Information
  • Founded
  • IDYA 2015
  • PHIN 2023
  • Country
  • IDYA United States
  • PHIN United States
  • Employees
  • IDYA N/A
  • PHIN N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • PHIN
  • Sector
  • IDYA Health Care
  • PHIN
  • Exchange
  • IDYA Nasdaq
  • PHIN Nasdaq
  • Market Cap
  • IDYA 2.3B
  • PHIN 2.1B
  • IPO Year
  • IDYA 2019
  • PHIN N/A
  • Fundamental
  • Price
  • IDYA $32.18
  • PHIN $52.02
  • Analyst Decision
  • IDYA Buy
  • PHIN Buy
  • Analyst Count
  • IDYA 17
  • PHIN 5
  • Target Price
  • IDYA $48.20
  • PHIN $57.20
  • AVG Volume (30 Days)
  • IDYA 1.3M
  • PHIN 354.6K
  • Earning Date
  • IDYA 11-04-2025
  • PHIN 10-28-2025
  • Dividend Yield
  • IDYA N/A
  • PHIN 2.08%
  • EPS Growth
  • IDYA N/A
  • PHIN N/A
  • EPS
  • IDYA N/A
  • PHIN 2.18
  • Revenue
  • IDYA $7,000,000.00
  • PHIN $3,427,000,000.00
  • Revenue This Year
  • IDYA $90.17
  • PHIN $2.00
  • Revenue Next Year
  • IDYA $219.42
  • PHIN $1.96
  • P/E Ratio
  • IDYA N/A
  • PHIN $23.81
  • Revenue Growth
  • IDYA N/A
  • PHIN N/A
  • 52 Week Low
  • IDYA $13.45
  • PHIN $36.25
  • 52 Week High
  • IDYA $33.64
  • PHIN $59.88
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 67.18
  • PHIN 35.05
  • Support Level
  • IDYA $28.17
  • PHIN $52.68
  • Resistance Level
  • IDYA $33.64
  • PHIN $55.82
  • Average True Range (ATR)
  • IDYA 1.68
  • PHIN 1.42
  • MACD
  • IDYA 0.40
  • PHIN 0.03
  • Stochastic Oscillator
  • IDYA 80.76
  • PHIN 24.38

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About PHIN PHINIA Inc.

Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.

Share on Social Networks: